December 2025 delivered a research landscape defined by a single, provocative question: how much of chronic disease management can diet accomplish on its own? Across eight studies spanning three continents, investigators pitted whole-food dietary patterns against conditions that have long been considered the domain of pharmaceuticals — irritable bowel syndrome, Crohn’s disease, psoriasis, chronic low back pain, and metabolic liver disease. The results are uneven, sometimes astonishing, and consistently instructive.
The month’s most contentious publication — a risk-stratified systematic review of saturated fat and cardiovascular outcomes — reignited a debate that has smoldered since the 1960s, complete with a provocative editorial and a sharp public rebuttal from the review authors. Meanwhile, the Mediterranean diet continued its march across medical specialties, demonstrating superiority over standard dietary advice for IBS and producing psoriasis clearance rates in the MEDIPSO trial that rival biologic therapy. In pediatric gastroenterology, the TASTI-MM trial showed that a palatable whole-food diet could match exclusive enteral nutrition for Crohn’s disease induction — while patients actually tolerated it.
Beyond dietary patterns, this month brought the largest placebo-controlled cannabis trial ever conducted for chronic pain, a meta-analysis quantifying the neuroprotective potential of healthful plant-based diets across 709,703 participants, a negative saffron trial that is more illuminating than many positive ones, and the first three-arm RCT demonstrating that time-restricted eating matches calorie restriction for reducing liver fat in MASLD. Together, these studies illustrate a field maturing rapidly — moving from observational associations toward interventional evidence, from blanket recommendations toward risk-stratified, personalized guidance.
Studies at a Glance
The Saturated Fat Debate & Mediterranean Diet Patterns
Two landmark trials this month challenge dietary orthodoxies from opposite directions — one reframing the saturated fat debate through risk stratification, the other positioning the Mediterranean diet as a first-line IBS intervention that outperforms standard dietary advice.
The relationship between dietary saturated fat and cardiovascular disease has been contested terrain for over half a century. Previous systematic reviews have produced pooled estimates suggesting modest benefits from saturated fat reduction, but these overall summaries mask critical heterogeneity in baseline cardiovascular risk, replacement nutrients, and trial quality. This review sought to resolve a persistent clinical question: does reducing saturated fat matter equally for everyone, or does the answer depend on who you are and what you eat instead?
Systematic review of RCTs comparing interventions to reduce or modify saturated fat intake against usual diet. Searched MEDLINE, Embase, and Cochrane Central Register from inception through July 2025. 17 RCTs enrolling 66,337 adults with minimum 2-year follow-up.
Show full methodology
Risk-stratified by 5-year baseline cardiovascular risk (low: <5%, moderate: 5–20%, high: ≥20%). Subgroup analysis by replacement nutrient. GRADE methodology applied. 4 trials rated low risk of bias; 13 rated high risk.
For surrogate endpoints, saturated fat reduction produced a mean decrease in total cholesterol of −0.34 mmol/L (13 mg/dL) across 14 RCTs (moderate certainty) and an LDL-cholesterol reduction of −0.15 mmol/L across 6 RCTs (high certainty).
For clinical endpoints, overall pooled estimates all favored intervention but none reached statistical significance: all-cause mortality RR 0.96 (0.88–1.06), cardiovascular mortality RR 0.93 (0.77–1.11), nonfatal MI RR 0.86 (0.70–1.06), stroke RR 0.83 (0.58–1.19).
Risk stratification revealed the critical gradient. At low baseline risk (<5%), absolute reductions fell below clinical importance thresholds. At high risk (≥20%): 6 fewer deaths per 1,000 and, with PUFA replacement, 21 fewer nonfatal MIs per 1,000 (RR 0.75, 95% CI 0.58–0.99; P for interaction = 0.05). The replacement nutrient matters profoundly: only PUFA replacement showed statistically significant MI reduction.
Strengths
- Pre-specified risk stratification — resolves contradictions in prior literature
- Large pooled sample (66,337 participants)
- GRADE methodology systematically applied
- Replacement nutrient subgroup analysis with interaction testing
Limitations
- 13 of 17 trials rated high risk of bias
- Most trials from 1960s–70s when SFA intake was 18–20% (now 11–13%)
- WHI — the largest trial — designed for breast cancer, not SFA reduction
- No overall clinical outcomes reached statistical significance
This review supports a personalized, risk-stratified approach to saturated fat counseling. For low-risk clients, aggressive SFA restriction is not supported as a priority. For clients with elevated cardiovascular risk — established CVD, metabolic syndrome, elevated ApoB — counseling to replace SFA with PUFA-rich whole foods (nuts, seeds, fatty fish, olive oil) has moderate-certainty evidence of clinically meaningful benefit. The quality of the replacement nutrient matters more than the mere act of SFA reduction.
IBS dietary management has been dominated by the low-FODMAP diet — effective for symptom reduction, but raising concerns about dietary diversity, microbiome depletion, and long-term sustainability. The Mediterranean diet offers a mechanistically plausible alternative that is inherently anti-inflammatory and gut-supportive without the restriction burden.
Randomized noninferiority trial on an online virtual platform (UK). 139 adults (mean age 40.4, 80% women) with moderate-to-severe IBS (baseline IBS-SSS 309). Randomized to Mediterranean diet (n=68) vs traditional dietary advice (n=71) for 6 weeks.
Show full methodology
All IBS subtypes included: 48% mixed, 31% diarrhea, 21% constipation. Modified intention-to-treat. NCT05985018.
The Mediterranean diet achieved a 62% clinical response rate (95% CI 50–73%) versus 42% for traditional dietary advice (31–55%), yielding a between-group difference of 20 percentage points (95% CI 4–36; P = 0.017). The Mediterranean diet met both noninferiority and demonstrated statistical superiority.
On continuous IBS-SSS scores: Mediterranean diet −101.2 versus TDA −64.5, between-group difference −36.7 (95% CI −70.5 to −2.8; P = 0.034). Abdominal pain frequency was specifically and significantly improved. MEDAS adherence scores confirmed dietary compliance (P < 0.001).
Strengths
- Pragmatic online design enhances real-world applicability
- All IBS subtypes included
- Demonstrated both noninferiority and superiority
- NNT of 5 compares favorably with pharmacological interventions
Limitations
- Short duration (6 weeks) — long-term effects unknown
- No low-FODMAP comparator arm despite original protocol
- 80% female sample limits male generalizability
- No biological outcome measures (inflammatory markers, microbiome)
The Mediterranean diet can be recommended as a first-line dietary approach for IBS, particularly for patients who find low-FODMAP overly restrictive. An NNT of 5 is strong enough to warrant dietary counseling as a primary intervention. The anti-inflammatory profile provides a mechanistic rationale beyond symptom management, and the specific improvement in abdominal pain frequency makes this particularly relevant for pain-predominant presentations.
Whole Foods Against Inflammatory Disease
Two RCTs test dietary interventions against autoimmune and inflammatory conditions where drug therapy dominates — and both deliver results that challenge the pharmacology-first paradigm.
Exclusive enteral nutrition (EEN) is the gold standard for pediatric Crohn’s induction (60–85% remission), but dropout rates routinely exceed 50%. The TASTI-MM investigators asked: could a palatable, whole-food diet that patients actually enjoy eating achieve comparable outcomes?
Multicenter (17 international sites), open-label, blinded-endpoint (PROBE) RCT. 83 biologic-naïve children and young adults (mean age 14.5 ± 3.7 years, range 6–25) with mild-to-moderate Crohn’s within first year of diagnosis.
Show full methodology
Randomized 1:1: Tasty & Healthy whole-food diet (n=41; excludes processed food, gluten, red meat, dairy — no formula required) vs EEN (n=42). 8 weeks with weekly dietary support. Primary outcome: tolerability. NCT04239248.
Tolerability was dramatically superior: 88% of T&H vs 52% of EEN completed the intervention (adjusted OR 7.7, 95% CI 2.4–25, P < 0.001). Only 15% of T&H patients discontinued versus 59% of EEN patients.
Per-protocol: EEN slightly higher (76% vs 67%, P = 0.47) — confirming EEN works when tolerated. Both diets reduced CRP, ESR, and calprotectin significantly. The T&H diet improved alpha-diversity while EEN decreased it. Ruminococcus gnavus decreased with T&H but increased with EEN (q < 0.001).
Strengths
- 17-center international PROBE design
- Head-to-head vs gold-standard EEN
- Metagenomics analysis (not just 16S rRNA)
- Both ITT and per-protocol analyses reported
Limitations
- Small sample (n=83) — may be underpowered for remission
- High differential dropout complicates ITT interpretation
- 8-week duration — maintenance of remission unknown
- Biologic-naïve only; may not generalize to refractory disease
The TASTI-MM trial shifts the question from “which diet induces best remission?” to “which diet will patients complete?” A diet with 56% remission and 88% tolerability may be more clinically useful than one with 76% remission and 52% tolerability. The favorable microbiome trajectory suggests longer-term advantages for gut ecology. For practitioners, this offers a realistic, food-based alternative for young Crohn’s patients.
Psoriasis is increasingly recognized as a systemic inflammatory condition with metabolic and cardiovascular comorbidities. While observational data suggested associations between Mediterranean diet adherence and lower severity, no randomized trial had directly tested a structured Mediterranean diet intervention. MEDIPSO is the first.
Open-label, single-center, evaluator-blinded RCT. 38 adults (mean age 46.4, 66% male) with mild-to-moderate psoriasis (PASI 2–10) on stable topical therapy only.
Show full methodology
16-week dietitian-guided Mediterranean diet (n=19) modeled on PREDIMED — including monthly counseling and weekly provision of 500 mL EVOO (≥4 tbsp/day) — vs standard low-fat dietary advice (n=19). Primary outcome: PASI change, assessed by blinded evaluator. NCT06257641.
The Mediterranean diet group achieved a mean PASI reduction of −3.4 (95% CI −4.4 to −2.4) while controls showed no change: 0.0 (−1.0 to 1.0). Between-group difference: −3.4 (95% CI −4.8 to −2.0; P < 0.001). PASI 75 response: 9/19 (47.4%) vs 0/19 (0%) — this level of clearance is typically seen with biologic therapies.
These improvements occurred without significant weight loss, suggesting anti-inflammatory mechanisms drove the benefit. Completion rate: 97.4%.
Strengths
- Evaluator-blinded PASI assessment
- PREDIMED-modeled intervention protocol
- 97.4% completion rate
- First RCT of Mediterranean diet for psoriasis
Limitations
- Very small sample (n=38) — requires replication
- Unequal intervention intensity (dietitian + free olive oil vs advice)
- Mild-to-moderate disease only; excludes systemic/biologic patients
- Single-center (Madrid) — cultural/dietary baseline effects
While the sample size demands caution, the magnitude is difficult to dismiss. A 47.4% PASI 75 response without systemic medication — if confirmed — would establish the Mediterranean diet as a primary therapeutic tool for mild-to-moderate psoriasis. The HbA1c reduction confirms metabolic co-benefits relevant to psoriasis’s cardiovascular comorbidity burden. Practitioners have a new, however preliminary, evidence base for intensive dietary intervention.
Plant Compounds and Mental Health
A meta-analysis and a negative RCT together illuminate what dietary and botanical interventions can — and cannot — do for mental and neurocognitive health, with the quality distinction proving decisive.
While Mediterranean and DASH diets have accumulated strong evidence for depression prevention, less is known about plant-based dietary patterns specifically — and critically, whether the quality of plant foods consumed modifies the association. This meta-analysis addressed that gap by distinguishing between healthy and unhealthy plant-based diet indices.
Systematic review with meta-analysis (PRISMA + MOOSE). 23 studies, 709,703 adults (53% female). Analyzed three plant-based diet indices: overall PDI, healthful PDI (hPDI), and unhealthful PDI (uPDI).
Show full methodology
Searched PubMed, Scopus, Web of Science through March 2024. hPDI: whole grains, fruits, vegetables, nuts, legumes, tea/coffee. uPDI: refined grains, fruit juice, SSBs, sweets. Random-effects with Sidik-Jonkman estimator. PROSPERO CRD42024524053.
Cross-sectional (highest vs lowest hPDI): anxiety OR 0.67 (0.46–0.96), depression OR 0.74 (0.57–0.96), psychological distress OR 0.51 (0.39–0.65).
Prospective (highest vs lowest hPDI): depression RR 0.77 (0.67–0.88), cognitive decline RR 0.74 (0.64–0.85), dementia RR 0.85 (0.76–0.96).
The critical finding: protective associations were driven by hPDI. Companion data showed uPDI was associated with increased dementia risk: HR 1.17 (1.03–1.33). Eating more plants is not automatically protective — quality determines neuroprotective potential.
Strengths
- 709,703 participants across 23 studies
- Pre-registered protocol (PROSPERO)
- Critically distinguishes healthy vs unhealthy plant-based indices
- Both cross-sectional and prospective analyses reported separately
Limitations
- All observational studies — cannot establish causality
- GRADE certainty likely low to very low for most outcomes
- Potential residual confounding
- Search limited to three databases
The 23% depression reduction and 26% cognitive decline reduction are clinically meaningful — comparable to moderate-intensity exercise. The critical counseling point: processed and refined plant foods do not confer protection and may increase neurodegeneration risk. Recommendations should be specific: whole grains, legumes, nuts, fruits, vegetables, tea, and coffee — not fruit juice, refined grains, and processed snacks marketed as “plant-based.”
Saffron has accumulated substantial evidence for clinical depression with effect sizes comparable to SSRIs. This trial tested whether saffron works upstream — in the subclinical, prodromal phase where preventive intervention could be most valuable.
Randomized, double-blind, placebo-controlled trial. 51 healthy adults with subclinical depressive symptoms. 30 mg/day saffron extract vs placebo for 6 weeks.
Show full methodology
Standardized to >2.5% crocines, >1.5% safranal; 15 mg twice daily. Primary outcome: composite z-score from BDI-II, STAI-YA, and MFI-20. Secondary: SF-12, inflammatory markers (CRP, IL-6, TNF-α), cortisol, metabolomics. NCT05690126.
The primary outcome was negative. Saffron 30 mg/day for 6 weeks did not significantly improve the composite z-score versus placebo. Individual symptom categories (depression, anxiety, fatigue) were also non-significant.
A secondary signal emerged: SF-12 mental health component showed significant time-by-treatment interaction favoring saffron (P = 0.04), with a 9.2-point between-group difference. No effects on inflammatory markers (CRP, IL-6, TNF-α) or cortisol — undermining the hypothesized anti-inflammatory mechanism. Metabolomics revealed saffron modulated N-acetyl-phenylalanine (tryptophan/neurotransmitter pathway).
Strengths
- Rigorous double-blind, placebo-controlled, pre-registered design
- Multi-modal assessment (mood, inflammation, HPA axis, metabolomics)
- Novel focus on subclinical population (prevention-oriented)
- Standardized extract with defined bioactive content
Limitations
- Small sample (N=51) — limited statistical power
- Composite primary endpoint may dilute domain-specific signals
- 6-week duration may be insufficient for subclinical effects
- Subclinical population has limited room for measurable improvement
This trial is more instructive as a negative result than many positive trials. It suggests saffron’s established efficacy for clinical depression may not extend to subclinical presentations at 30 mg/day for 6 weeks. The negative inflammatory findings challenge the anti-inflammatory mechanism hypothesis. For practitioners, this argues against recommending saffron as a preventive intervention for subclinical low mood. Saffron’s evidence base remains strongest for diagnosed depression.
Novel Interventions — Cannabis for Pain and Time-Restricted Eating
The largest-ever cannabis pain trial and a three-arm TRE study both answer pragmatic clinical questions — not whether the intervention works in theory, but whether it works well enough to change practice.
Cannabis-based medicines have been widely adopted for chronic pain despite a thin evidence base — most prior trials were small, short, and used variable preparations. This is the largest placebo-controlled cannabis study for chronic pain ever undertaken, using a chemically defined, standardized full-spectrum extract across 66 centers in Germany and Austria.
Phase 3, multicenter (66 sites), double-blind, placebo-controlled RCT. 820 adults with chronic low back pain (mean age 52.2, 57% female, baseline NRS ~6.0).
Show full methodology
VER-01 extract: 2.5 mg THC, 0.1 mg CBG, 0.02 mg CBD per dose + terpenes/flavonoids in sesame oil — notably THC-dominant with minimal CBD. Oral administration, 3-week titration, max 32.5 mg THC/day. Phase A: 12-week double-blind. Phase B: 6-month open-label. Phase D: randomized withdrawal (n=116). Followed EMA/FDA pain guidelines. NCT04940741.
Neuropathic subgroup (n=179) showed enhanced efficacy: NPSI difference −7.3 (95% CI −13.2 to −1.3; P = 0.017).
VER-01 participants used half the rescue NSAIDs: 10.5 vs 18.3 tablets (P < 0.001). PGIC improvement: 45.1% vs 23.4% (NNTB 4.6). In open-label extension: 73.9% achieved ≥30% pain reduction. Phase D randomized withdrawal: HR 0.75 (0.44–1.27; NS), though pain increase on withdrawal was significant (P = 0.034). Dizziness 42.8% vs 5.2%; discontinuation due to AEs 17.3% vs 3.5%. No dependence or withdrawal symptoms detected.
Strengths
- Largest placebo-controlled cannabis pain trial (N=820)
- Standardized, chemically defined extract
- Multi-phase design including open-label and withdrawal phases
- Comprehensive safety including addiction/withdrawal assessment
Limitations
- 0.6-point NRS difference is below some MID thresholds (1 point)
- Dizziness (43%) could compromise blinding
- Phase D withdrawal did not meet primary endpoint
- THC-dominant formulation not representative of high-CBD products
The clinical utility lies in the responder rate: 1 in 2 patients achieves meaningful pain reduction, and rescue NSAID use is halved — meaningful for patients with GI or cardiovascular NSAID contraindications. The neuropathic subgroup showed larger effects, supporting pain phenotyping when discussing cannabis. Practitioners should note this is a THC-dominant product (not high-CBD), and dizziness (43%) requires counseling about driving and occupational safety.
MASLD affects ~30% of the global adult population, and calorie restriction remains the evidence-based cornerstone — but adherence is notoriously difficult. Time-restricted eating (TRE) constrains eating to a daily window without explicit calorie restriction, but lacked a three-arm comparison against both calorie restriction and standard care.
16-week, 3-arm, parallel-group RCT. 337 adults with overweight/obesity and MASLD (South Korea). Randomized 1:1:1 to standard of care, calorie restriction, or time-restricted eating 16:8 protocol.
Show full methodology
SOC (n=113), CR (n=110), TRE (n=110). Primary outcome: change in hepatic steatosis by MRI-PDFF (gold standard). NCT05579158.
TRE produced 4.6% body weight loss (CR: 4.1%), ~9% visceral fat reduction (comparable to CR), and similar improvements in glucose homeostasis, lipid profiles, liver stiffness, and sleep quality. SOC showed minimal changes with a 3% visceral fat increase. No serious adverse events in any group.
Strengths
- Three-arm design — active comparator plus true control
- Large sample for dietary RCT (N=337)
- Gold-standard MRI-PDFF measurement
- Adequate duration (16 weeks) for metabolic outcomes
Limitations
- Open-label (blinding impossible in dietary trials)
- Single-country (South Korea) — may limit generalizability
- Absolute MRI-PDFF values not available in public sources
- No long-term follow-up beyond 16 weeks
TRE replaces the most burdensome component of dietary management (calorie counting) with a simple binary rule (eat within 8 hours). The 25.8% liver fat reduction is clinically meaningful and comparable to pharmaceutical interventions. For practitioners managing MASLD clients who struggle with food logging, 16:8 TRE is a simpler, evidence-based entry point that achieves equivalent metabolic outcomes. The absence of serious adverse events reinforces TRE as well-tolerated.
Synthesis & Emerging Themes
Diet as Precision Medicine
A unifying thread across December’s research is the shift from blanket dietary recommendations toward precision, context-dependent application. The saturated fat review demonstrates this most clearly: the same intervention — reducing saturated fat intake — produces clinically meaningful benefit for high-risk individuals and negligible benefit for low-risk populations. The TASTI-MM trial extends this logic to IBD: the “best” diet for Crohn’s induction is not the one with the highest per-protocol remission rate, but the one patients can actually follow. The cannabis trial reinforces precision through its neuropathic pain subgroup finding — the same extract shows larger effects when matched to the right pain phenotype.
The Mediterranean Diet’s Expanding Evidence Base
December 2025 marks another milestone in the Mediterranean diet’s progression from cardiovascular intervention to multi-system therapeutic tool. Its IBS efficacy (NNT = 5), psoriasis clearance rates (47.4% PASI 75), and metabolic improvements (HbA1c −4.1 mmol/mol) span three medical specialties and three distinct pathophysiological mechanisms — gut-brain axis modulation, systemic immune regulation, and metabolic optimization. For nutrition practitioners, the Mediterranean diet is increasingly the evidence-based default recommendation across conditions — not because it is generic, but because its anti-inflammatory, prebiotic, and immunomodulatory properties align with common pathological mechanisms.
The Quality Spectrum of Plant-Based Eating
The plant-based diet meta-analysis delivers a message that practitioners need to internalize: not all plant foods are created equal. The 23% reduction in depression risk associated with healthy plant-based diets coexists with a 17% increase in dementia risk from unhealthy plant-based diets. This is not a theoretical distinction — it is the difference between clinical benefit and clinical harm. The saffron trial adds nuance: even among well-studied botanical compounds, translating evidence from clinical to subclinical populations is not straightforward.
Negative Results as Positive Knowledge
The saffron trial deserves recognition precisely because its primary outcome was negative. In a publication landscape biased toward positive results, a well-designed negative trial provides essential calibration. Saffron’s established efficacy for clinical depression does not extend to subclinical symptoms at 30 mg/day for 6 weeks. The absence of anti-inflammatory marker changes challenges a proposed mechanism. For evidence-based practitioners, knowing where the evidence stops is as valuable as knowing where it begins.
Gaps and Questions for January
Several questions emerge from this month’s evidence that January’s literature should address. How durable are the MEDIPSO psoriasis improvements beyond 16 weeks? Can the TASTI-MM whole-food diet serve as a maintenance strategy after induction? What is the optimal eating window for TRE in MASLD — would a 10-hour window produce similar effects with better adherence? And as cannabis regulation evolves, will we see trials comparing THC-dominant versus CBD-dominant versus balanced formulations head-to-head?
The evidence base for nutrition-as-medicine continued to build this month — not through incremental confirmation of what we already knew, but through risk-stratified reanalysis of contested questions, head-to-head trials against gold-standard comparators, and honest reporting of negative results. This is what a maturing field looks like.